Key Metrics
Factor Lens
Seasonal Performance
Dividends
Per-share amounts adjusted for stock splits.
Last 12 Payouts
| Period | Ex-Date | Amount / Share |
|---|---|---|
| Q2 2026 | ~2026-06-30 | $0.5300 |
| Q1 2026 | ~2026-03-31 | $0.5300 |
| Q2 2025 | ~2025-06-30 | $0.5000 |
| Q1 2025 | ~2025-03-31 | $0.5000 |
| Q2 2024 | ~2024-06-30 | $0.4320 |
| Q1 2024 | ~2024-03-31 | $0.4320 |
| Q2 2023 | ~2023-06-30 | $0.3750 |
| Q1 2023 | ~2023-03-31 | $0.3750 |
| Q2 2022 | ~2022-06-30 | $0.3250 |
| Q1 2022 | ~2022-03-31 | $0.3250 |
| Q2 2021 | ~2021-06-30 | $0.2500 |
| Q1 2021 | ~2021-03-31 | $0.2500 |
Financial Trends
Revenue & Net Income
Earnings Per Share
Margins
Cash Flow
Company Overview
Zoetis Inc. is a global leader in the animal health industry, focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products… and services, biodevices, genetic tests and precision animal health. The company has a diversified business with approximately 300 comprehensive product lines commercialized across eight core species: dogs, cats and horses (companion animals) and cattle, swine, poultry, fish and sheep (livestock); and within seven major product categories: parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals and animal health diagnostics. Companion animal products represented approximately 70% of revenue for 2025, while livestock products represented approximately 29%, with the remaining 1% from Client Supply Services (contract manufacturing) and human health diagnostics. The company operates in two segments: United States (54% of revenue) and International (45% of revenue). With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, pet owners, and livestock producers worldwide. The company also provides solutions in biodevices, genetic testing and precision animal health.
- Name
- Zoetis Inc.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Kristin C. Peck · Chief Executive Officer
- Employees
- 14,500 as of 2025-12-31
- IPO Date
- 2020-01-14
- Phone
- (973) 822-7000
- Address
- 10 Sylvan Way, Parsippany, NJ 07054
- Website
- www.zoetis.com
Key Executives
| Name | Title | FY Pay |
|---|---|---|
| Roxanne Lagano | Executive Vice President, General Counsel and Corporate Secretary | — |
| Kristin C. Peck | Chief Executive Officer | — |
Latest News
- 2026-04-25
- 2026-04-24
-
2026-04-24
Cwm LLC Reduces Holdings in Zoetis Inc. $ZTS defenseworld.net
-
2026-04-22
IDEXX Laboratories Vs. Zoetis: A Pre-Earnings Comparison seekingalpha.com
- 2026-04-20
-
2026-04-17
Zoetis Inc. $ZTS Shares Sold by Berkeley Inc defenseworld.net
- 2026-04-16
- 2026-04-15